Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.

ABSTRACT:

Background

Although real-life results of sofosbuvir/simeprevir have been extensively reported from the United States, data from other geographical areas are limited. In the French observational cohort, ANRS CO22 HEPATHER, 9432 patients were given the new oral antivirals from December 2013 to June 30, 2018. We report the results of sofosbuvir/simeprevir in genotypes 1- and 4-infected patients.

Methods

Demographics and history of liver disease were collected at entry in the cohort. Clinical, adverse events, and virological data were collected throughout treatment and post-treatment follow-up. The choice of treatment duration or addition of ribavirin was left up to the physician.

Results

Five hundred ninety-nine HCV (467 genotype 1 and 132 genotype 4) mono-infected, naïv

SUBMITTER: Laurain A 

PROVIDER: S-EPMC6446259 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature